Targeted Bone Support: High-Dose Vitamin D and Calcium Improve Bone Mineral Density in Adolescents with HIV and Baseline Insufficiency
Highlights
The VITALITY trial, a large-scale randomized controlled study, investigated the impact of vitamin D and calcium on bone health in adolescents living with HIV. Key findings include:
- Overall, high-dose vitamin D3 (20,000 IU weekly) and calcium carbonate (500 mg daily) did not show a statistically significant difference in bone mineral density across the entire study population.
- In a crucial subgroup analysis, participants with baseline vitamin D insufficiency showed significant improvements in lumbar spine bone mineral apparent density (LS-BMAD) after 48 weeks of supplementation.
- The intervention was found to be safe, with no drug-related severe adverse events reported, supporting its potential as a low-cost public health intervention.
- Vitamin D insufficiency was highly prevalent (76%) among adolescents with HIV in the study regions of Zimbabwe and Zambia, highlighting a significant unmet clinical need.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.